Utah Medical Products, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2020
January 28, 2021 at 09:00 am
Share
Utah Medical Products, Inc. announced earnings results for the fourth quarter ended December 31, 2020. For the fourth quarter, the company announced sales was USD 12.010 million compared to USD 11.831 million a year ago. Operating income was USD 4.280 million compared to USD 4.679 million a year ago. Net income was USD 3.412 million compared to USD 4.359 million a year ago. Diluted earnings per share from continuing operations was USD 0.934 compared to USD 1.165 a year ago. For the full year, sales was USD 42.178 million compared to USD 46.904 million a year ago. Operating income was USD 13.708 million compared to USD 17.633 million a year ago. Net income was USD 10.798 million compared to USD 14.727 million a year ago. Diluted earnings per share from continuing operations was USD 2.941 compared to USD 3.939 a year ago.
Utah Medical Products, Inc. is engaged in the business of producing medical services. The Company markets a range of medical devices used in critical care areas, especially the neonatal intensive care unit (NICU), the labor and delivery (L&D) department and the women's health center in hospitals, as well as medical devices sold to outpatient clinics and physician's offices. Its products include BT-CATH, CVX-RIPE, AROM-COT, MUC-X, CORDGUARD, DISPOSA-HOOD, DELTRAN PLUS, GESCO, PICC-NATE, LETZ System, Filshie Clip System, PATHFINDER PLUS, SUPRAPUBIC CATHETERIZATION, LIBERTY System, ENDOCURETTE, LUMIN, and BioPharm HP-PRT, among others. BT-CATH is a uterine balloon tamponade catheter for controlling severe postpartum hemorrhage. MUC-X is an aspiration device used immediately after birth to clear neonatal respiratory passages and reduce exposure to potential infections. AROM-CO is a finger cover with a prong designed to rupture maternal membranes with less patient pain and anxiety.
UTAH MEDICAL PRODUCTS, INC. 
